Phaseline

Companies › Cytokinetics

Cytokinetics: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 2 Phase 3, 2 Phase 2, 1 Phase 4; Cardiovascular; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Aficamten–Phase 3Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy; Pediatric; Hypertrophic Cardiomyopathy (HCM)Nov 2026
Omecamtiv Mecarbil
Cardiac myosin activator
MYH7, MYH6, MYH7B, MYL3, MYL2Phase 3Heart FailureSep 2027
CK-4021586 (ulacamten)–Phase 2Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06793371CK-4021586 (ulacamten)Phase 2Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)CardiovascularSep 2026
NCT06081894AficamtenPhase 3Symptomatic Non-Obstructive Hypertrophic CardiomyopathyCardiovascularNov 2026
NCT07600177AficamtenPhase 4Hypertrophic Cardiomyopathy (HCM)CardiovascularDec 2026
NCT06736574Omecamtiv MecarbilPhase 3Heart FailureCardiovascularSep 2027
NCT06412666AficamtenPhase 2PediatricCardiovascularJan 2030

From the company's SEC filings

Cash and short-term investments of $1.6bn on 2026-09-30; operating cash outflow about $576m a year; runway about 33 months at that burn, to Jul 2029; 2 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MYH7 (1) MYH6 (1) MYH7B (1) MYL3 (1) MYL2 (1)

Companies with the same targets

Bristol-Myers Squibb Kardigan Bayer

Companies built like this

Kardigan Braveheart Bio iVascular S.L.U. Inhibikase Therapeutics Grace Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.